Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Manual Syringe Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

NCT01662856
View directory record Official record
Conditions
Vascular Surgical Bleeding
Interventions
Fibrin Sealant Grifols, Manual Compression
Biological · Procedure
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Florence, Alabama • Palo Alto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 4, 2026, 12:10 PM EDT
Completed No phase listed Observational

LMA Cuff Pressure and LMA-induced Complications

NCT01385969
View directory record Official record
Conditions
Sore Throat, Dysphagia, Dysphonia
Interventions
Standard inflation of LMA cuff, Pressure check with syringe recoil, Pressure check by pressure transducer
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
View directory record Official record
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Financial Incentives to Promote Stimulant Abstinence in a Community-Based Syringe Exchange Program

NCT05787847
View directory record Official record
Conditions
Stimulant Use
Interventions
Incentives for Abstinence, Health Education
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522
View directory record Official record
Conditions
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

NCT03913260
View directory record Official record
Conditions
Healthy
Interventions
LY3375880, Buffer Matrix (No LY3375880), Autoinjector (AI), Manual Syringe
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome

NCT01190891
View directory record Official record
Conditions
Shoulder Impingement Syndrome
Interventions
Manual Physical Therapy, Corticosteroid Injection
Procedure
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

NCT07210320
View directory record Official record
Conditions
Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions
Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray
Drug
Lead sponsor
Insignis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Proximal Protection With The Mo.Ma Device During Carotid Stenting

NCT00744523
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Mo.Ma cerebral protection device
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 4, 2026, 12:10 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

NCT04052880
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
Drug
Lead sponsor
Larysa Sanchez
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

NCT05681715
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Orange, California • San Francisco, California • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 4, 2026, 12:10 PM EDT
Completed No phase listed Observational Results available

DyeVert™ Plus Contrast Reduction System Multicenter Observational Study

NCT03715452
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
DyeVert Plus Contrast Reduction System
Device
Lead sponsor
Osprey Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Torrance, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional

Thoracentesis QI Study

NCT05424120
View directory record Official record
Conditions
Pleural Effusion
Interventions
Manual aspiration, Wall suction, Vacuum bottle drainage
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

NCT02673619
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Umeclidinium, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Omaha, Nebraska • Raleigh, North Carolina • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional

Community Supported Risk Reduction for Syringe Exchange Participants

NCT02654366
View directory record Official record
Conditions
Substance Use Disorders, Risk Reduction
Interventions
Risk Reduction Group
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NCT01949844
View directory record Official record
Conditions
Coronary Artery Disease, CAD
Interventions
regadenoson, Optimark®, Myocardial perfusion MRI
Drug · Device
Lead sponsor
Daniel S. Berman
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
Device · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

NCT01524770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Phase 4 Interventional Results available

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

NCT00990288
View directory record Official record
Conditions
Blood Loss
Interventions
Hemostatic Matrix
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 4, 2026, 12:10 PM EDT
Recruiting Not applicable Interventional

A Comparison of Cyclic Manual Direct Aspiration Thrombectomy (Plunger Technique) vs. Static Manual Direct Aspiration Thrombectomy for Treatment of Acute Large Vessel Occlusion Stroke

NCT07231380
View directory record Official record
Conditions
Acute Ischemic Stroke Patients, Large Vessel Occlusion
Interventions
Plunger Technique, Static Manual Aspiration Thrombectomy
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 4, 2026, 12:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor

NCT01942356
View directory record Official record
Conditions
Acute Cholecystitis, Chronic Cholecystitis
Interventions
TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia, TIVA - Tachycardia, INH - Hypotension, INH - Hypertension, INH - Bradycardia, INH - Tachycardia
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Sep 4, 2026, 12:10 PM EDT